JHOP Articles

Original Research, Renal-Cell Carcinoma, Dose Escalation/Reduction, Tyrosine Kinase Inhibitor

Reduced Starting Dose of Tyrosine Kinase Inhibitors in Patients with Metastatic Renal-Cell Carcinoma

Tia M. Stitt, PharmD; Katherine M. Saunders, PharmD, BCOP; Brooke C. Rowling, PharmD Candidate; Jennifer L. Waller, PhD; Amber B. Clemmons, PharmD, BCOP, FHOPA

Original Research, Clinical Trials, Oncology Pharmacy Programs/Protocols

Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials

Jacqueline Saunders, PharmD, BCPS; Sumati Murli, PhD; Michelle A. Rudek, PharmD, PhD; Anand Khandoobhai, PharmD, MS; Anne DeLisa, PharmD, CCRP; Amy Goodrich, RN, MSN, CRNP-AC; Janet Mighty, BS Pharm, MBA

Meeting Highlights

Biosimilars, ASCO Highlights, Oncology Pharmacy Programs/Protocols

Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice

Original Research, Biosimilars, Transplant

Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization

Trace Bartels, PharmD; Molly Klanderman, PhD, MS; Jaime Rogers, MSN, RN; Kristin Gray, MSN, RN; Heidi Kosiorek, MS; Chris Coughlin, PharmD, BCOP

Meeting Highlights

Biosimilars, ASCO Highlights

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma